Atara Biotherap(ATRA.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Atara Biotherap
ATRA.US
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases.
1.813 T
ATRA.USMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
D
BiotechnologyIndustry
Industry Ranking280/387
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE20.49%A
    • Profit Margin-40.91%E
    • Gross Margin75.97%A
  • Growth ScoreD
    • Revenue YoY-88.41%E
    • Net Profit YoY39.47%B
    • Total Assets YoY-67.77%E
    • Net Assets YoY32.25%A
  • Cash ScoreC
    • Cash Flow Margin273.32%A
    • OCF YoY-88.41%E
  • Operating ScoreC
    • Turnover0.56C
  • Debt ScoreE
    • Gearing Ratio286.59%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    21:12 ETATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

    prnewswire·
    US
    ATRA
    -4.49%
    US
    IXJ
    +0.51%
    US
    LABU
    -6.92%
    prnewswire·
    US
    ATRA
    -4.49%
    US
    IXJ
    +0.51%
    US
    LABU
    -6.92%

    15:00 ETAtara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

    prnewswire·
    US
    ATRA
    -4.49%
    US
    BBH
    -1.03%
    US
    FBT
    -0.66%
    prnewswire·
    US
    ATRA
    -4.49%
    US
    BBH
    -1.03%
    US
    FBT
    -0.66%

    10:34 ETATRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

    prnewswire·
    US
    ATRA
    -4.49%
    US
    VHT
    +0.30%
    US
    XBI
    -2.31%
    prnewswire·
    US
    ATRA
    -4.49%
    US
    VHT
    +0.30%
    US
    XBI
    -2.31%

    Atara Biotherapeutics (ATRA) to Release Earnings on Thursday

    Market Beat·
    US
    ATRA
    -4.49%
    US
    ARKG
    -0.14%
    US
    LABU
    -6.92%
    Market Beat·
    US
    ATRA
    -4.49%
    US
    ARKG
    -0.14%
    US
    LABU
    -6.92%

    Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress | ATRA Stock News

    StockTitan·
    US
    ATRA
    -4.49%
    US
    IBB
    -1.68%
    US
    FBT
    -0.66%
    StockTitan·
    US
    ATRA
    -4.49%
    US
    IBB
    -1.68%
    US
    FBT
    -0.66%
    © 2026 Longbridge｜Disclaimer